Space Finco, Inc. acquires Avid Bioservices, Inc. (2024)

Deal facts

Buyer: Space Finco, Inc.
Target: Avid Bioservices, Inc.
Deal value: Not disclosed
Announced: 6 November 2024
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates

5 Feb 2025CompletedClosed
Space Finco, Inc. completes acquisition of Avid Bioservices, Inc.
Introductory Note This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Merger (as defined below) pursuant to the Agreement and Plan of Merger, dated November 6, 2024 (the “Merger Agreement”), by and among Avid Bioservices, Inc., a Delaware corporation (the “Company”), Space Finco, Inc., a Delaware corporation (“Parent”), and Space Mergerco, I
Source
5 Feb 2025CompletedClosed
Space Finco, Inc. completes acquisition of Avid Bioservices, Inc.
Introductory Note This Current Report on Form 8-K is being filed in connection with the completion of the previously announced Merger (as defined below) pursuant to the Agreement and Plan of Merger, dated November 6, 2024 (the “Merger Agreement”), by and among Avid Bioservices, Inc., a Delaware corporation (the “Company”), Space Finco, Inc., a Delaware corporation (“Parent”), and Space Mergerco, I
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Avid Bioservices, Inc by Space Finco, Inc. This deal, announced on 6 November 2024, represents a classic going private transaction within the US healthcare sector. The buyer, Space Finco, Inc, has moved to take the target off the public markets using an all cash consideration. There is no disclosed value attached to this transaction in the public record, which is a notable feature for a completed deal of this nature. The absence of a public price tag often suggests a negotiated settlement between sophisticated parties where the final number remains confidential, yet the certainty of cash execution is the primary driver for the seller.

For the SME founder reading this, the mechanics here are instructive. A going private deal removes the target from the glare of quarterly reporting and short term market sentiment. The use of all cash consideration eliminates the risk of share price volatility affecting the final payout, a common pain point in stock based deals. However, this structure also implies a clean break. Unlike a merger where earn outs or contingent value rights might bridge valuation gaps, an all cash deal usually demands a single agreed figure. This places a premium on accurate due diligence and precise valuation modelling before the deal hits the market. The buyer assumes full risk post completion, while the target shareholders receive immediate liquidity without further exposure to the business.

The regulatory context for a US domestic healthcare deal of this size typically involves standard antitrust review, though the lack of disclosed value makes it difficult to gauge if specific competition thresholds were triggered. The swift completion suggests that any necessary regulatory clearances from bodies like the CMA equivalent in the US were secured without significant delay. This efficiency is a hallmark of well structured private equity or strategic buyouts where the parties align on the commercial logic early. It demonstrates that even in a complex sector like healthcare, a straightforward cash offer can cut through market noise and deliver a definitive exit.

You should review your current capital structure this week to identify any covenants that might restrict a future going private sale. Specifically, check your debt agreements for change of control clauses that could trigger immediate repayment if you ever seek a similar all cash exit. Knowing these constraints now prevents the deal from stalling at the final hurdle when a buyer makes an offer.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More going private deals More from Space Finco, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

13 October 2026Firm intentionHealthcare

ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.

ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…

Buyer: ArcheNova Technology Co., Ltd
Target: ArcheNova Biotech Corp.
Deal value: USD 2,000,000,000
Deal type: going private

Read deal Healthcare deals going private deals Cayman Islands deals

5 October 2026Firm intentionHealthcare

Onyx Bidco LLC to acquire Option Care Health, Inc.

Onyx Bidco LLC has agreed to acquire Option Care Health, Inc. in a cash transaction. The deal, announced on 5 October 2026, involves the US-based buyer purchasing the US…

Buyer: Onyx Bidco LLC
Target: Option Care Health, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

28 September 2026Firm intentionHealthcare

Lifecore Inc. to acquire Lifecore Biomedical, Inc.

Lifecore Inc. has agreed to acquire Lifecore Biomedical, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 28 September 20…

Buyer: Lifecore Inc.
Target: Lifecore Biomedical, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

7 September 2026Firm intentionHealthcare

TULIP UK BIDCO LIMITED to acquire Spire Healthcare Group plc

TULIP UK BIDCO LIMITED has agreed to acquire Spire Healthcare Group plc in a going private transaction valued at approximately GBP 1.0265 billion. The deal structure inv…

Buyer: TULIP UK BIDCO LIMITED
Target: Spire Healthcare Group plc
Deal value: GBP 1,026,500,000
Deal type: going private

Read deal Healthcare deals going private deals United Kingdom deals

3 August 2026In reviewHealthcare

Curium US Holdings LLC to acquire Lantheus Holdings, Inc.

Curium US Holdings LLC has agreed to acquire Lantheus Holdings, Inc. in a transaction designed to take the healthcare company private. The deal was announced on 3 August…

Buyer: Curium US Holdings LLC
Target: Lantheus Holdings, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history

Space Finco, Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive

Space Finco, Inc. to acquire Avid Bioservices, Inc.

Deal facts

Explore the Toolkit

Deal timeline

Browse adjacent archives

Similar deals

ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.

Onyx Bidco LLC to acquire Option Care Health, Inc.

Lifecore Inc. to acquire Lifecore Biomedical, Inc.

TULIP UK BIDCO LIMITED to acquire Spire Healthcare Group plc

Curium US Holdings LLC to acquire Lantheus Holdings, Inc.

Space Finco, Inc.

How this page is built